Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct;59(10):6437-43.
doi: 10.1128/AAC.00845-15. Epub 2015 Aug 3.

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin

D R Snydman  1 , L A McDermott  2 , N V Jacobus  2 , C Thorpe  3 , S Stone  2 , S G Jenkins  4 , E J C Goldstein  5 , R Patel  6 , B A Forbes  7 , S Mirrett  8 , S Johnson  9 , D N Gerding  9
Affiliations

U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin

D R Snydman et al. Antimicrob Agents Chemother. 2015 Oct.

Abstract

In 2011 a surveillance study for the susceptibility to fidaxomicin and epidemiology of Clostridium difficile isolates in the United States was undertaken in seven geographically dispersed medical centers. This report encompasses baseline surveillance in 2011 and 2012 on 925 isolates. A convenience sample of C. difficile isolates or toxin positive stools from patients were referred to a central laboratory. Antimicrobial susceptibility was determined by agar dilution (CLSI M11-A8). Clinical and Laboratory Standards Institute (CLSI), Food and Drug Administration, or European Union of Clinical Antimicrobial Susceptibility Testing (EUCAST) breakpoints were applied where applicable. Toxin gene profiles were characterized by multiplex PCR on each isolate. A random sample of 322 strains, stratified by institution, underwent restriction endonuclease analysis (REA). The fidaxomicin MIC90 was 0.5 μg/ml for all isolates regardless of REA type or toxin gene profile, and all isolates were inhibited at ≤1.0 μg/ml. By REA typing, BI strains represented 25.5% of the isolates. The toxin gene profile of tcdA, tcdB, and cdtA/B positive with a tcdC 18-bp deletion correlated with BI REA group. Moxifloxacin and clindamycin resistance was increased among either BI or binary toxin-positive isolates. Metronidazole and vancomycin showed reduced susceptibility (EUCAST criteria) in these isolates. Geographic variations in susceptibility, REA group and binary toxin gene presence were observed. Fidaxomicin activity against C. difficile isolated in a national surveillance study did not change more than 1 year after licensure. This analysis provides baseline results for future comparisons.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Comparison of toxin gene profile by REA typing for strains REA typed.
FIG 2
FIG 2
Map of sites and C. difficile toxin gene profile distributions among seven medical centers in 2011 and 2012.
See this image and copyright information in PMC

References

    1. Labbe AC, Poirier L, MacCannell D, Louie T, Savoie M, Beliveau C, Laverdiere M, Pepin J. 2008. Clostridium difficile infections in a Canadian tertiary care hospital before and during regional epidemic associated with the BI/NAP1/027 strain. Antimicrob Agents Chemother 52:3180–3187. doi:10.1128/AAC.00146-08. - DOI - PMC - PubMed
    1. Taori SK, Hall V, Poxton IR. 2010. Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 59:338–344. doi:10.1099/jmm.0.014829-0. - DOI - PubMed
    1. Goldstein EJG, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. 2011. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection. Antimicrob Agents Chemother 55:5194–5199. doi:10.1128/AAC.00625-11. - DOI - PMC - PubMed
    1. Baines SD, O'Connor R, Freeman J, Fawley WN, Harmanus C, Mastrantonio P, Kuijper EJ, Wilcox WH. 2008. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 62:1046–1052. doi:10.1093/jac/dkn313. - DOI - PubMed
    1. Citron DM, Babakhani F, Goldstein EJC, Nagaro K, Sambol S, Sears P, Shue Y-K, Gerding DN. 2009. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection. Anaerobe 15:234–236. doi:10.1016/j.anaerobe.2009.09.005. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources